drugset / Trial / NCT02177838

Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer

NCT02177838

NaSingle-groupOpen-labelTreatment

Summary

This pilot clinical trial studies cetuximab and radiation therapy in treating patients with stage III-IV head and neck cancer. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways by targeting certain cells. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cetuximab or cisplatin together with radiation therapy may kill more tumor cells.

Timeline

Start
2015-03-25
Primary completion
2019-08-22
Completion
2019-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody Intravenous
Subject Cisplatin Other / unclassified Intravenous